De Keyser J, Zwanikken C, Boon M
Department of Neurology, Academisch Ziekenhuis Groningen, The Netherlands.
J Neurol Sci. 1998 Jul 15;159(1):51-3. doi: 10.1016/s0022-510x(98)00139-7.
Despite reports that influenza vaccination appears to be safe in multiple sclerosis there is uncertainty which patients may benefit from it. By using a questionnaire we compared the effects of influenza illness (1995-1996 season) and influenza vaccination (autumn of 1996) on neurologic symptoms in patients with multiple sclerosis registered in the Groningen Multiple Sclerosis Data Bank. No clinically relevant effects were reported in 53 patients with primary progressive multiple sclerosis, either following vaccination or the illness. In a group of 180 patients with relapsing multiple sclerosis, an exacerbation occurred within the following 6 weeks in 33% after influenza illness, whereas it occurred in only 5% after vaccination. The exacerbation rate following influenza illness was significantly higher regardless of whether patients were essentially restricted to wheelchair or not. Because of a substantial greater risk of relapse after influenza illness than after vaccination, annual influenza vaccination should be offered routinely to all patients with relapsing multiple sclerosis.
尽管有报道称流感疫苗接种在多发性硬化症患者中似乎是安全的,但对于哪些患者可能从中受益仍存在不确定性。我们通过问卷调查,比较了流感疾病(1995 - 1996年季节)和流感疫苗接种(1996年秋季)对格罗宁根多发性硬化症数据库中登记的多发性硬化症患者神经症状的影响。53例原发性进行性多发性硬化症患者在接种疫苗或患病后均未报告有临床相关影响。在一组180例复发型多发性硬化症患者中,流感疾病后6周内33%的患者病情加重,而接种疫苗后仅5%的患者病情加重。无论患者是否基本限于轮椅活动,流感疾病后的病情加重率均显著更高。由于流感疾病后复发的风险比接种疫苗后大得多,应常规为所有复发型多发性硬化症患者每年接种流感疫苗。